Evidence map›Paper›PMID 32314552›Full record

ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology2020

Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.

Prashant Dogra, Joseph D Butner, Sara Nizzero, Javier Ruiz Ramírez, Achraf Noureddine, María J Peláez, Dalia Elganainy, Zhen Yang, Anh-Dung Le, Shreya Goel and 5 more

Abstract readReview
In one paragraph

Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Rational nanoparticle design: Optimization using insights from experiments and mathematical models.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Review
  6. Immune-checkpoint inhibitor therapy response evaluation using oncophysics-based mathematical models.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  7. Article
  8. Article
  9. Zonal Intratumoral Delivery of Nanoparticles Guided by Surface Functionalization.Langmuir : the ACS journal of surfaces and colloids · 2022
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. A Multiscale Model to Identify Limiting Factors in Nanoparticle-Based miRNA Delivery for Tumor InhibitionAnnual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2021
    Article
  17. Imaging-guided nanomedicine development.Current opinion in chemical biology · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Prashant DograMathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0001-6722-7371
Joseph D ButnerMathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas, USA.
Sara NizzeroMathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas, USA.
Javier Ruiz RamírezMathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas, USA.
Achraf NoureddineDepartment of Chemical and Biological Engineering, University of New Mexico, Albuquerque, New Mexico, USA.
María J PeláezMathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas, USA.
Dalia ElganainyDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zhen YangCenter for Bioenergetics, Houston Methodist Research Institute, Houston, Texas, USA.
Anh-Dung LeNanoscience and Microsystems Engineering, University of New Mexico, Albuquerque, New Mexico, USA.
Shreya GoelCancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hon S LeongBiological Sciences Platform, Sunnybrook Research Institute, Toronto, Ontario, Canada.
Eugene J KoayDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
C Jeffrey BrinkerDepartment of Chemical and Biological Engineering and UNM Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico, USA.
Vittorio CristiniMathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0002-7909-4278
Zhihui WangMathematics in Medicine Program, Houston Methodist Research Institute, Houston, Texas, USA.ORCID 0000-0001-6262-700X

Funding

Transport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$9.3M
Imaging and Molecular Correlates of Progression in Cystic Neoplasms of the PancreasU01CA196403 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MAITRA, ANIRBAN · 2015 to 2020
$5.8M
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate CancerR01CA226537 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI ARAP, WADIH, BRINKER, C JEFFREY · 2018 to 2022
$3.2M
miR-155 targeted therapeutics for precision medicine in lung cancerR01CA222007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., CRISTINI, VITTORIO · 2018 to 2022
$2.6M
Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modelingU01CA213759 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOPEZ-BERESTEIN, GABRIEL · 2017 to 2021
$2.5M
NCI NIH HHS R01 CA222007NCI NIH HHS R01 CA226537NCI NIH HHS U01 CA196403NCI NIH HHS U01 CA213759NCI NIH HHS U54 CA210181NIH HHS 1R01CA222007NIH HHS 1R01CA226537NIH HHS 1U01CA196403NIH HHS 1U01CA213759NIH HHS U54CA210181
6 · The paper itself

Abstract

While plasma concentration kinetics has traditionally been the predictor of drug pharmacological effects, it can occasionally fail to represent kinetics at the site of action, particularly for solid tumors. This is especially true in the case of delivery of therapeutic macromolecules (drug-loaded nanomaterials or monoclonal antibodies), which can experience challenges to effective delivery due to particle size-dependent diffusion barriers at the target site. As a result, disparity between therapeutic plasma kinetics and kinetics at the site of action may exist, highlighting the importance of target site concentration kinetics in determining the pharmacodynamic effects of macromolecular therapeutic agents. Assessment of concentration kinetics at the target site has been facilitated by non-invasive in vivo imaging modalities. This allows for visualization and quantification of the whole-body disposition behavior of therapeutics that is essential for a comprehensive understanding of their pharmacokinetics and pharmacodynamics. Quantitative non-invasive imaging can also help guide the development and parameterization of mathematical models for descriptive and predictive purposes. Here, we present a review of the application of state-of-the-art imaging modalities for quantitative pharmacological evaluation of therapeutic nanoparticles and monoclonal antibodies, with a focus on their integration with mathematical models, and identify challenges and opportunities. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Diagnostic Tools > in vivo Nanodiagnostics and Imaging Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.

Indexed as

Antibodies, MonoclonalImage Processing, Computer-AssistedNanostructuresAnimalsCell Line, TumorHumansMiceModels, TheoreticalNeoplasmsTheranostic NanomedicineXenograft Model Antitumor AssaysAntibodies, Monoclonalmathematical modelingmonoclonal antibodiesnanoparticlesnoninvasive imagingpharmacokinetics

Identifiers

PMID32314552
PMCPMC7507140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.